These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 4681306)

  • 1. Serum phosphorus control in dialysis patients with aluminum hydroxide gel-containing cookies.
    Ogden DA; Hurley E; Witt E; Heitsman C; Cazee C
    Proc Clin Dial Transplant Forum; 1972; 2():166-70. PubMed ID: 4681306
    [No Abstract]   [Full Text] [Related]  

  • 2. Disappearance of vascular calcifications during treatment of renal osteodystrophy. Two patients treated with high doses of vitamin D and aluminum hydroxide.
    Verberckmoes R; Bouillon R; Krempien B
    Ann Intern Med; 1975 Apr; 82(4):529-33. PubMed ID: 1119767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aluminum and renal osteodystrophy in chronic uremia.
    Berland Y; Grandvuillemin M; Charhon S; Olmer M
    Kidney Int Suppl; 1985 Dec; 17():S183-7. PubMed ID: 3867793
    [No Abstract]   [Full Text] [Related]  

  • 4. Can renal bone disease be prevented?
    Shaldon S
    Proc Eur Dial Transplant Assoc; 1973; 10(0):91-123. PubMed ID: 4808119
    [No Abstract]   [Full Text] [Related]  

  • 5. Rational nursing care in chronic renal disease.
    Lavandero R; Davis V
    Am J Nurs; 1979 Nov; 79(11):1938, 1941. PubMed ID: 258954
    [No Abstract]   [Full Text] [Related]  

  • 6. Calcium carbonate and magnesium hydroxide in the prevention of renal osteodystrophy or the demise of aluminum toxicity in uremia. Analysis of 5 years experience.
    Morinière P; Fournier A; Westeel PF; Idrissi A; Renaud H; Hocine C; Belbrik S; Marie A; Leflon P; Sebert JL
    Contrib Nephrol; 1988; 64():58-73. PubMed ID: 3053039
    [No Abstract]   [Full Text] [Related]  

  • 7. Fluoride and dialysis osteodystrophy: results of a double-blind study.
    Oreopoulos DG; Taves DR; Rabinovich S; Meema HE; Murray T; Fenton SS; deVeber GA
    Trans Am Soc Artif Intern Organs; 1974; 20A():203-8. PubMed ID: 4615422
    [No Abstract]   [Full Text] [Related]  

  • 8. Renal osteodystrophy in course of periodic dialysis for chronic uremia.
    Kim D; Bell NH; Bundesen W; Putong P; Simon NM; Walker C; Del Greco F
    Trans Am Soc Artif Intern Organs; 1968; 14():367-71. PubMed ID: 5701557
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effects of water purification on renal osteodystrophy in the patients with regular hemodialysis therapy].
    Masuyama J; Tachibana Y
    Nihon Jinzo Gakkai Shi; 1984 Apr; 26(4):407-16. PubMed ID: 6471583
    [No Abstract]   [Full Text] [Related]  

  • 10. The management of uremia.
    Hamburger RJ
    Am Fam Physician; 1977 Sep; 16(3):125-32. PubMed ID: 331923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Some characteristics of phosphorus-calcium metabolism and the bone system pathology in chronic uremia].
    Ermolenko VM; Nikiforova NV; Migunova NA; Bochman NL; Rassokhin BM
    Ter Arkh; 1973 May; 45(5):70-8. PubMed ID: 4768378
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of renal osteopathy].
    Keller F; Schwarz A; Kraft D
    Fortschr Med; 1985 Mar; 103(10):268-70. PubMed ID: 3979935
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum-aluminum in nondialyzed chronic uremic patients before and during treatment with aluminum-containing phosphate-binding gels.
    Brahm M
    Clin Nephrol; 1986 May; 25(5):231-5. PubMed ID: 3720033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoride metabolism in uremia.
    Nielsen E; Solomon N; Goodwin NJ; Siddhivarn N; Galonsky R; Taves D; Friedman EA
    Trans Am Soc Artif Intern Organs; 1973; 19():450-5. PubMed ID: 4722761
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effects of aluminum gels on renal osteodystrophy caused by chronic hemodialysis. Increase in the total surface of osseous resorption in anephric patients].
    Fournier A; Tunchot S; Bedrossians J; Idatte JM; Bordier P
    Sem Hop; 1974 Nov; 50(45):2803-10. PubMed ID: 4375854
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of calcium and phosphorus on patients maintained on dialysis.
    Goldsmith RS; Arnaud CD; Johnson WJ
    Kidney Int Suppl; 1975 Jan; (2):118-22. PubMed ID: 1099298
    [No Abstract]   [Full Text] [Related]  

  • 17. Calcium carbonate. A better phosphate binder than aluminum hydroxide.
    Lerner A; Kramer M; Goldstein S; Caruana R; Epstein S; Raja R
    ASAIO Trans; 1986; 32(1):315-8. PubMed ID: 3535845
    [No Abstract]   [Full Text] [Related]  

  • 18. Aluminum toxicity in relation to kidney disorders.
    King SW; Savory J; Wills MR
    Ann Clin Lab Sci; 1981; 11(4):337-42. PubMed ID: 7023347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma aluminium levels in patients on maintenance haemodialysis fall when oral aluminium hydroxide is withdrawn.
    Wallace MR; Pybus J
    N Z Med J; 1983 Oct; 96(742):793-5. PubMed ID: 6578451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumoral calcinosis in uremic patients: a reply to Dietl et al.
    Ionova D; Zlatarska S
    Clin Nephrol; 2000 Jun; 53(6):489. PubMed ID: 10879672
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.